Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMA970A + CV8102 + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Immatics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Peptides, Covalent Small Molecules → Small Molecules, RNA Therapeutics → Nucleic Acid Therapeutics, Classical Binding Small Molecules → Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intratumoral, Oral, Intravenous
01
Overview
IMA970A + CV8102 + cyclophosphamide is an investigational combination therapy primarily under evaluation for the treatment of hepatocellular carcinoma (HCC). IMA970A is a peptide-based cancer vaccine designed to stimulate an immune response against tumor-associated antigens in HCC. CV8102 is a synthetic RNA-based immunostimulant that acts as a Toll-like receptor 7/8 (TLR7/8) agonist and retinoic acid-inducible gene I (RIG-I) agonist to enhance innate and adaptive immune responses. Cyclophosphamide is an alkylating agent used as chemotherapy and immunosuppressant; in this combination, it may be used at low doses to reduce regulatory T cells and enhance vaccine-induced anti-tumor immunity. The combination aims to synergistically boost anti-tumor immune responses by combining antigen-specific vaccination with broad immune activation and modulation.
- Other names
- cytophosphane
02
Targets
γδ TCR (T-cell receptor)DDX58 (Retinoic acid-inducible gene I protein)HLA-I/II (Human leukocyte antigen class I and II molecules)DNATLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on IMA970A + CV8102 + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMA970A + CV8102 + cyclophosphamide.